Biomarkers Unbound - The Supreme Court's Ruling on Diagnostic-Test Patents

[Guest guest]

A recent Supreme Court ruling limiting the ability to patent basic genetic research and biomarkers may have significant impact on future medical costs (good news) and perhaps on private-sector investments in medical technology (maybe bad news).

Past patent monopolies on genetic technology such as the patenting of the BRAC genes affecting breast (and to a lessor extent prostate) cancers may be reversed as the legal community argues over implementation of this decision.

And, this decision will undoubtedly have ramifications in the search for, and cost of implementing, better prostate cancer biomarkers.

See "Biomarkers Unbound - The Supreme Court's Ruling on Diagnostic-Test Patents" at: http://www.nejm.org/doi/full/10.1056/NEJMp1204164

The Best to You and Yours!

Jon in Nevada